Guided Therapeutics Inc (OTCBB:GTHP) Keeps Falling

[[tagnumber 0]][[tagnumber 1]]The performance of Guided Therapeutics Inc (OTCBB:GTHP)’s stock has been rather bad in recent months and the stock is sliding deeper below the 10 cent per share mark. After a rather decent upward run that was fueled by optimistic PR we saw the ticker slide even more steeply on increased volumes.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]By now [[tagnumber 6]]GTHP[[tagnumber 7]] has reached a new 52–week low and it doesn’t seem like it will stop falling. Meanwhile, the market cap of the ticker is rather small compared to other OTC healthcare–orientated companies, while the numbers contained in the latest report coming from the company are pretty decent.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $1.97 million[[tagnumber 13]] [[tagnumber 12]]current assets: $3.26 million[[tagnumber 13]] [[tagnumber 12]]current liabilities: $4.79 million[[tagnumber 13]] [[tagnumber 12]]quarterly revenues: $103 thousand[[tagnumber 13]] [[tagnumber 12]]quarterly net loss: $1.7 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]What’s even more impressive about [[tagnumber 6]]GTHP[[tagnumber 7]] is the fact that it is actually generating revenues. Unfortunately, the cost of goods sold is around two times bigger than the actual revenues the company is registering, but this might change in the future.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]As we previously noted [[tagnumber 6]]GTHP[[tagnumber 7]] had it pretty rough last week. After a 6.05% drop in Friday’s session, we saw the ticker drop to a 52–week low of $0.0357. A total of 2.4 million shares changed their owners and generated $86 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]It seems like drop slide is slowing its speed, so [[tagnumber 6]]GTHP[[tagnumber 7]] might become a bit more stable. This doesn’t mean that you should skip on doing your due diligence and weighing out the risks before putting any money on the line.[[tagnumber 2]]